Produção Nacional
Revisado por pares
Is cysteamine use effective in the treatment of melasma? A systematic review and meta‐analysis
2022; Wiley; Volume: 35; Issue: 12 Linguagem: Inglês
10.1111/dth.15961
ISSN1529-8019
AutoresAgenor Gomes dos Santos Neto, Ísis Carolline Valério da Silva, Carlisson R. Melo, Adilson Allef Moraes Santana, Ricardo Luiz Cavalcanti de Albuquerque Júnior,
Tópico(s)Skin Protection and Aging
ResumoDermatologic TherapyVolume 35, Issue 12 e15961 REVIEW ARTICLE Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis Agenor Gomes dos Santos-Neto, Corresponding Author Agenor Gomes dos Santos-Neto [email protected] orcid.org/0000-0003-3698-1456 Department of Morphology and Experimental Pathology, Institute of Technology and Research, Aracaju, Sergipe, Brazil Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, Brazil Correspondence Agenor Gomes dos Santos-Neto, Av. Murilo Dantas, 300, Building of Institute of Technology and Research, District of Farolândia, Aracaju, Sergipe, CEP 49032-490, Brazil. Email: [email protected]Search for more papers by this authorÍsis Carolline Valério da Silva, Ísis Carolline Valério da Silva School of Medicine, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this authorCarlisson Ramos Melo, Carlisson Ramos Melo Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this authorAdilson Allef Moraes Santana, Adilson Allef Moraes Santana Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this authorRicardo Luiz Cavalcanti de Albuquerque-Junior, Ricardo Luiz Cavalcanti de Albuquerque-Junior Department of Morphology and Experimental Pathology, Institute of Technology and Research, Aracaju, Sergipe, Brazil Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this author Agenor Gomes dos Santos-Neto, Corresponding Author Agenor Gomes dos Santos-Neto [email protected] orcid.org/0000-0003-3698-1456 Department of Morphology and Experimental Pathology, Institute of Technology and Research, Aracaju, Sergipe, Brazil Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, Brazil Correspondence Agenor Gomes dos Santos-Neto, Av. Murilo Dantas, 300, Building of Institute of Technology and Research, District of Farolândia, Aracaju, Sergipe, CEP 49032-490, Brazil. Email: [email protected]Search for more papers by this authorÍsis Carolline Valério da Silva, Ísis Carolline Valério da Silva School of Medicine, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this authorCarlisson Ramos Melo, Carlisson Ramos Melo Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this authorAdilson Allef Moraes Santana, Adilson Allef Moraes Santana Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this authorRicardo Luiz Cavalcanti de Albuquerque-Junior, Ricardo Luiz Cavalcanti de Albuquerque-Junior Department of Morphology and Experimental Pathology, Institute of Technology and Research, Aracaju, Sergipe, Brazil Health and Environment Postgraduate Program, Tiradentes University, Aracaju, Sergipe, BrazilSearch for more papers by this author First published: 25 October 2022 https://doi.org/10.1111/dth.15961Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Melasma is a recurrent hypermelanosis disorder characterized by the appearance of brownish and symmetrical spots on the skin. It affects the quality of life and is resistant to available treatment approaches. Cysteamine has been reported as a promising depigmenting agent for melasma treatment and following formulation enhancement, its use is being reported. This review aimed to evaluate the efficacy of the use of depigmenting formulations containing 5% cysteamine in the treatment of patients with melasma. A systematic search was performed in PubMed, Science Direct, and Scielo databases until December 27, 2021, based on criteria selected by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Statistical analysis was performed with Review Manager 5.4 software. The risk of bias was assessed using the Cochrane Risk of Bias Tool for Randomized Trials. A total of six studies containing 120 melasma patients treated with 5% cysteamine were included in this meta-analysis. The meta-analysis demonstrated that 5% cysteamine is effective for the treatment of patients with melasma (MD 6.26 [95% CI 3.68–8.83], p < 0.0001, I2 = 86%). In this review, through meta-analysis allows concluding that 5% cysteamine is effective in the treatment of melasma and presents a low probability of side or adverse effects. CONFLICT OF INTEREST The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created or analyzed in this study. Volume35, Issue12December 2022e15961 RelatedInformation
Referência(s)